{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:37:43Z","timestamp":1792111063730,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10557-022-07379-z","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T09:11:07Z","timestamp":1663146667000},"page":"799-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"38","author":[{"given":"Jie","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-3790","authenticated-orcid":false,"given":"Fengshuang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"issue":"1","key":"7379_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/nu8010023","volume":"8","author":"JM Lee","year":"2016","unstructured":"Lee JM, Lee H, Kang S, Park WJ. Fatty Acid Desaturases, Polyunsaturated Fatty Acid Regulation, and Biotechnological Advances. Nutrients. 2016;8(1):23. https:\/\/doi.org\/10.3390\/nu8010023.","journal-title":"Nutrients"},{"issue":"1-4","key":"7379_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0163-7827(86)90092-5","volume":"25","author":"Y Tamura","year":"1986","unstructured":"Tamura Y, Hirai A, Terano T, et al. Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan. Prog Lipid Res. 1986;25(1-4):461\u20136.","journal-title":"Prog Lipid Res"},{"issue":"19","key":"7379_CR3","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJM198505093121901","volume":"312","author":"D Kromhout","year":"1985","unstructured":"Kromhout D, Bosschieter EB, De Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312(19):1205\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"7379_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1753-4887.1998.tb06133.x","volume":"56","author":"NF Sheard","year":"1998","unstructured":"Sheard NF. Fish consumption and risk of sudden cardiac death. Nutr Rev. 1998;56(6):177\u20139.","journal-title":"Nutr Rev"},{"issue":"21","key":"7379_CR5","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1161\/01.CIR.0000038493.65177.94","volume":"106","author":"PM Kris-Etherton","year":"2002","unstructured":"Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747\u201357.","journal-title":"Circulation"},{"key":"7379_CR6","unstructured":"ReportLinker. Omega-3 Market by Type, Application, Source and Region\u2014Global Forecasts to 2025. Published December 2019. https:\/\/www.reportlinker.com\/p03670113\/Omega-3-PUFA-Marketby-TypeApplication-Source-Sub-source-Region-GlobalForecasts-to.html?utm_source=PRN.\u00a0Accessed 18 Feb 2021"},{"issue":"3","key":"7379_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","volume":"3","author":"T Aung","year":"2018","unstructured":"Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77\u00a0917 individuals. JAMA Cardiol. 2018;3(3):225\u201334.","journal-title":"JAMA Cardiol"},{"issue":"19","key":"7379_CR8","doi-asserted-by":"publisher","first-page":"e013543","DOI":"10.1161\/JAHA.119.013543","volume":"8","author":"Y Hu","year":"2019","unstructured":"Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. J Am Heart Assoc. 2019;8(19):e013543.","journal-title":"J Am Heart Assoc"},{"key":"7379_CR9","first-page":"100997","volume":"38","author":"SU Khan","year":"2021","unstructured":"Khan SU, Lone AN, Khan MS, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. EClin Med. 2021;38:100997.","journal-title":"EClin Med"},{"issue":"7","key":"7379_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12325-009-0045-2","volume":"26","author":"H Rupp","year":"2009","unstructured":"Rupp H. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Adv Ther. 2009;26(7):675\u201390.","journal-title":"Adv Ther"},{"key":"7379_CR11","first-page":"n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed). 2021;372:n71.","journal-title":"BMJ (Clinical research ed)"},{"key":"7379_CR12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2011;343:d5928.","journal-title":"BMJ (Clinical research ed)"},{"issue":"7414","key":"7379_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557\u201360.","journal-title":"BMJ (Clinical research ed)"},{"issue":"16","key":"7379_CR14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540\u201350.","journal-title":"N Engl J Med"},{"issue":"1","key":"7379_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"7379_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"7379_CR17","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH Randomized Clinical Trial. Jama. 2020;324(22):2268\u201380.","journal-title":"Jama"},{"issue":"6","key":"7379_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","volume":"143","author":"AA Kalstad","year":"2021","unstructured":"Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial. Circulation. 2021;143(6):528\u201339.","journal-title":"Circulation"},{"issue":"9567","key":"7379_CR19","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet (London). 2007;369(9567):1090\u20138.","journal-title":"Lancet (London)"},{"key":"7379_CR20","doi-asserted-by":"crossref","unstructured":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet (London). 1999;354(9177):447-55.","DOI":"10.1016\/S0140-6736(99)07072-5"},{"issue":"21","key":"7379_CR21","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","volume":"363","author":"D Kromhout","year":"2010","unstructured":"Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015\u201326.","journal-title":"N Engl J Med"},{"issue":"5","key":"7379_CR22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamainternmed.2014.328","volume":"174","author":"DE Bonds","year":"2014","unstructured":"Bonds DE, Harrington M, Worrall BB, et al. Effect of long-chain \u03c9-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Intern Med. 2014;174(5):763\u201371.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"7379_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/HJR.0b013e328339cc70","volume":"17","author":"G Einvik","year":"2010","unstructured":"Einvik G, Klemsdal TO, Sandvik L, et al. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehab. 2010;17(5):588\u201392.","journal-title":"Eur J Cardiovasc Prev Rehab"},{"issue":"9645","key":"7379_CR24","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2008;372(9645):1223\u201330.","journal-title":"Lancet (London, England)"},{"issue":"21","key":"7379_CR25","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","volume":"122","author":"B Rauch","year":"2010","unstructured":"Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152\u20139.","journal-title":"Circulation"},{"issue":"4","key":"7379_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"J Bosch","year":"2012","unstructured":"Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309\u201318.","journal-title":"N Engl J Med"},{"issue":"19","key":"7379_CR27","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","volume":"368","author":"MC Roncaglioni","year":"2013","unstructured":"Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800\u20138.","journal-title":"N Engl J Med"},{"key":"7379_CR28","doi-asserted-by":"publisher","first-page":"c6273","DOI":"10.1136\/bmj.c6273","volume":"341","author":"P Galan","year":"2010","unstructured":"Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ (Clinical research ed). 2010;341:c6273.","journal-title":"BMJ (Clinical research ed)"},{"issue":"15","key":"7379_CR29","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1161\/CIR.0000000000000482","volume":"135","author":"DS Siscovick","year":"2017","unstructured":"Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135(15):e867\u2013e84.","journal-title":"Circulation"},{"issue":"1","key":"7379_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"7379_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2022.06.1018","volume":"353","author":"A Alfaddagh","year":"2022","unstructured":"Alfaddagh A, Kapoor K, Dardari ZA, et al. Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention. Atherosclerosis. 2022;353:11\u20139.","journal-title":"Atherosclerosis"},{"issue":"1","key":"7379_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.trsl.2015.06.017","volume":"167","author":"FK Welty","year":"2016","unstructured":"Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. Translat Res :J Lab Clin Med. 2016;167(1):257\u201380.","journal-title":"Translat Res :J Lab Clin Med"},{"key":"7379_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2017.02.004","volume":"91","author":"JR Nelson","year":"2017","unstructured":"Nelson JR, Wani O, May HT, Budoff M. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017;91:1\u20139. https:\/\/doi.org\/10.1016\/j.vph.2017.02.004.","journal-title":"Vascul Pharmacol"},{"issue":"1","key":"7379_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2010.05.022","volume":"212","author":"AL Cawood","year":"2010","unstructured":"Cawood AL, Ding R, Napper FL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212(1):252\u20139.","journal-title":"Atherosclerosis"},{"issue":"1","key":"7379_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11883-019-0762-1","volume":"21","author":"R Preston Mason","year":"2019","unstructured":"Preston Mason R. New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atheroscler Rep. 2019;21(1):2.","journal-title":"Curr Atheroscler Rep"},{"key":"7379_CR36","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.biopha.2018.04.118","volume":"103","author":"RP Mason","year":"2018","unstructured":"Mason RP, Dawoud H, Jacob RF, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 2018;103:1231\u20137.","journal-title":"Biomed Pharmacother"},{"key":"7379_CR37","doi-asserted-by":"publisher","first-page":"102337","DOI":"10.1016\/j.plefa.2021.102337","volume":"173","author":"SCR Sherratt","year":"2021","unstructured":"Sherratt SCR, Dawoud H, Bhatt DL, et al. Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability. Prostaglandins Leukot Essent Fat Acids. 2021;173:102337.","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"issue":"25","key":"7379_CR38","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.121.055654","volume":"144","author":"B Gencer","year":"2021","unstructured":"Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine \u0277-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981\u201390.","journal-title":"Circulation"},{"issue":"1","key":"7379_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(18)30356-9","volume":"18","author":"DJ Seiffge","year":"2019","unstructured":"Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019;18(1):117\u201326.","journal-title":"Lancet Neurol"},{"issue":"7181","key":"7379_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nature06797","volume":"451","author":"N Mackman","year":"2008","unstructured":"Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914\u20138.","journal-title":"Nature"},{"issue":"10","key":"7379_CR41","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1161\/hs1001.097093","volume":"32","author":"R Saxena","year":"2001","unstructured":"Saxena R, Lewis S, Berge E, et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke. 2001;32(10):2333\u20137.","journal-title":"Stroke"},{"issue":"19","key":"7379_CR42","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1161\/CIRCULATIONAHA.107.704759","volume":"116","author":"M Sakabe","year":"2007","unstructured":"Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation. 2007;116(19):2101\u20139.","journal-title":"Circulation"},{"issue":"4","key":"7379_CR43","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1161\/CIRCEP.109.880773","volume":"2","author":"JH Rennison","year":"2009","unstructured":"Rennison JH, van Wagoner DR. Impact of dietary fatty acids on cardiac arrhythmogenesis. Circ Arrhythm Electrophysiol. 2009;2(4):460\u20139.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"11","key":"7379_CR44","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1540-8167.2005.50007.x","volume":"16","author":"DM Ninio","year":"2005","unstructured":"Ninio DM, Murphy KJ, Howe PR, et al. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol. 2005;16(11):1189\u201394.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"15","key":"7379_CR45","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jacc.2007.05.046","volume":"50","author":"JF Sarrazin","year":"2007","unstructured":"Sarrazin JF, Comeau G, Daleau P, et al. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs. J Am Coll Cardiol. 2007;50(15):1505\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"7379_CR46","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.jacc.2005.02.079","volume":"45","author":"L Cal\u00f2","year":"2005","unstructured":"Cal\u00f2 L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005;45(10):1723\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"7379_CR47","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.jacc.2013.07.014","volume":"62","author":"R Rodrigo","year":"2013","unstructured":"Rodrigo R, Korantzopoulos P, Cereceda M, et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol. 2013;62(16):1457\u201365.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"7379_CR48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jacc.2012.11.021","volume":"61","author":"A Macchia","year":"2013","unstructured":"Macchia A, Grancelli H, Varini S, et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol. 2013;61(4):463\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"7379_CR49","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1001\/jama.2012.28733","volume":"308","author":"D Mozaffarian","year":"2012","unstructured":"Mozaffarian D, Marchioli R, Macchia A, et al. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. Jama. 2012;308(19):2001\u201311.","journal-title":"Jama"},{"issue":"3","key":"7379_CR50","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.ijcard.2013.03.053","volume":"168","author":"S Kumar","year":"2013","unstructured":"Kumar S, Sutherland F, Lee JM, et al. Effects of high dose intravenous fish oil on human atrial electrophysiology: implications for possible anti- and pro-arrhythmic mechanisms in atrial fibrillation. Int J Cardiol. 2013;168(3):2754\u201360.","journal-title":"Int J Cardiol"},{"issue":"9","key":"7379_CR51","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCRESAHA.114.302226","volume":"114","author":"J Heijman","year":"2014","unstructured":"Heijman J, Voigt N, Nattel S, et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114(9):1483\u201399.","journal-title":"Circ Res"},{"issue":"2-3","key":"7379_CR52","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0014-2999(98)00528-7","volume":"356","author":"JC Macleod","year":"1998","unstructured":"Macleod JC, Macknight AD, Rodrigo GC. The electrical and mechanical response of adult guinea pig and rat ventricular myocytes to omega3 polyunsaturated fatty acids. Eur J Pharmacol. 1998;356(2-3):261\u201370.","journal-title":"Eur J Pharmacol"},{"issue":"24","key":"7379_CR53","doi-asserted-by":"publisher","first-page":"11000","DOI":"10.1073\/pnas.92.24.11000","volume":"92","author":"YF Xiao","year":"1995","unstructured":"Xiao YF, Kang JX, Morgan JP, et al. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci USA. 1995;92(24):11000\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7379_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12933-019-0887-0","volume":"18","author":"O Sheikh","year":"2019","unstructured":"Sheikh O, Vande Hei AG, Battisha A, et al. Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. Cardiovasc Diabetol. 2019;18(1):84.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"7379_CR55","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/0006-2952(96)00473-X","volume":"52","author":"HJ Kr\u00e4mer","year":"1996","unstructured":"Kr\u00e4mer HJ, Stevens J, Grimminger F, et al. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol. 1996;52(8):1211\u20137.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"7379_CR56","doi-asserted-by":"publisher","first-page":"C273","DOI":"10.1152\/ajpcell.00174.2012","volume":"304","author":"MK Larson","year":"2013","unstructured":"Larson MK, Tormoen GW, Weaver LJ, et al. Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation. Am J Physiol Cell Physiol. 2013;304(3):C273\u20139.","journal-title":"Am J Physiol Cell Physiol"},{"key":"7379_CR57","doi-asserted-by":"publisher","unstructured":"Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Mason RP, Bhatt DL. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on Interleukin-1\u03b2, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022 Aug 2;146(5):372\u2013379. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059410.","DOI":"10.1161\/CIRCULATIONAHA.122.059410"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07379-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:34:17Z","timestamp":1721792057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07379-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7379"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07379-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"31 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the submission of the manuscript; the manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}